Catalyst Dossier · compiled by Celia 🧫

Sanofi (SNYNF)

Biotechnology · market cap $99.8B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Sanofi (SNYNF) is a large-cap global biopharmaceutical company in the Biotechnology sector with approximately 74,846 employees and a market capitalization of roughly $99.8 billion. The company fields a broad pipeline spanning rare diseases, immunology, vaccines, oncology, and cardiovascular/metabolic indications, with several near-term Phase 2 and Phase 3 catalysts expected through early 2027. The most impactful upcoming readouts include a Phase 3 fitusiran data point (importance 9/10, est. August 2026) and a Phase 3 PCV21 readout (importance 9/10, est. January 2027).

The catalyst path

2026-08-05 (est.)Phase 2 · Amlitelimabimp 7/10
2026-08-15 (est.)Phase 3 · Fitusiranimp 9/10
2026-10-30 (est.)Phase 2 · venglustat (GZ402671)imp 7/10
2026-12-23 (est.)Phase 2 · frexalimabimp 7/10
2027-01-07 (est.)Phase 3 · PCV21imp 9/10
2027-03-25 (est.)Phase 3 · Clotting factor concentrates (CFC) or bypassing agents (BPA)imp 9/10

Pipeline

Asset	Phase	Indication
Teriflunomide (HMR1726)	Phase 3	Multiple Sclerosis
DTaP-IPV-HB-PRP~T vaccine	Phase 3	Diphtheria
SAR3419	Phase 2	Diffuse Large B-cell Lymphoma
XRP0038 (NV1FGF)	Phase 2	Peripheral Arterial Occlusive Disease
Insulin glargine/lixisenatide Fixed Ratio Combination	Phase 3	Type 2 Diabetes
Irbesartan	Phase 3	Atrial Fibrillation
Split, Inactivated, Trivalent Influenza Vaccine	Phase 2	Orthomyxoviridae Infection
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody	Phase 2	Systemic Sclerosis
Levofolinate	Phase 2	Colorectal Cancer Metastatic
teriflunomide HMR1726	Phase 3	Multiple Sclerosis
Mitoxantrone	Phase 3	Prostatic Neoplasms
rhIDU (recombinant human-Alpha-L-Iduronidase)	Phase 3	Mucopolysaccharidosis I
SR121463B	Phase 3	Inappropriate ADH Syndrome
Olipudase alfa	Phase 3	Sphingomyelin Lipidosis
Myozyme	Phase 3	Glycogen Storage Disease Type II
Itepekimab SAR440340	Phase 3	Chronic Obstructive Pulmonary Disease
Insulin glulisine QD	Phase 3	Type 2 Diabetes
G-CSF Plus Plerixafor	Phase 2	Lymphoma, Non-Hodgkin
frexalimab	Phase 2	Focal Segmental Glomerulosclerosis
XL147 (SAR245408)	Phase 2	Breast Cancer

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.